Hormonal
Semaglutide (GLP-1 receptor agonist) significantly reduces body weight, BMI, and waist circumference in overweight or obese adults, with or without type 2 diabetes, compared to placebo or other glucose-lowering medications.
If you are overweight or obese (BMI ≥24), semaglutide is a highly effective medical intervention for weight loss, working for both diabetic and non-diabetic individuals. It significantly reduces body weight, BMI, and waist circumference compared to placebo. While it can cause gastrointestinal side effects like nausea, serious adverse events are not more common than with a placebo. Be aware that stopping the medication may lead to weight regain, so long-term management and lifestyle changes are crucial.
Meta-analysis showed that compared with the control group, the semaglutide group was reduced more significantly in body weight (MD = −7.49, 95% CI [−9.92, −5.07], P < 0.001), body mass index (MD = −3.35, 95% CI [−4.79, −1.92], P < 0.001), waist circumference (MD = −7.26, 95% CI [−9.94, −4.58], P < 0.001)...
Why this rating
Based on a systematic review and meta-analysis of 15 RCTs involving 6984 patients, though heterogeneity was high.
Source
Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis
Yang Liu et al. · Journal of Research in Medical Sciences · 2024
DOI 10.4103/jrms.jrms_693_23
More from this paper
- Semaglutide significantly improves glycemic control (HbA1c and fasting blood glucose) and systolic blood pressure in overweight or obese adults, with or without type 2 diabetes.Good
- Semaglutide increases the proportion of patients achieving significant weight loss thresholds (>5%, >10%, >15%, and >20%) compared to control groups.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →